Scholarlink

Purpose <p>Postoperative delirium (POD) occurs in about one-third of patients and the incidence increases with age. The rate of missed delirium is 60%–70%, and there has recently been a shift from early detection and treatment to preventive strategies to reduce risk. While GABA<sub>A</sub> receptor agonists (GRAs) are a risk factor for delirium, discontinuation may also worsen delirium through withdrawal or worsening of insomnia. This study aimed to evaluate the effect of switching from daily preoperative GRA therapy to lemborexant monotherapy on the incidence of postoperative delirium.</p> Methods <p>A retrospective study was conducted in cancer patients aged ≥ 75&#xa0;years who visited the Department of Psycho-Oncology at the National Cancer Center Hospital in Japan and were taking a GRA daily for insomnia before surgery under general anesthesia. Delirium was screened at least once daily with the Nursing Delirium Screening Scale on postoperative days 0–6 (positive if ≥ 2). We used a two-group intention-to-treat (ITT) framework, classifying patients according to a psycho-oncologist–verified preoperative switch to lemborexant.</p> Results <p>Fifty patients satisfied eligibility. POD occurred in 1/17 (5.9%) in the Switch group and 15/33 (45.5%) in the Continue group; RD −39.6 percentage points (95% CI −59.9 to −19.2), RR 0.13 (95% CI 0.02–0.90), OR 0.08 (95% CI 0.01–0.63), <i>p</i> = 0.005.</p> Conclusion <p>A preoperative switch policy to lemborexant monotherapy was associated with a lower observed risk of POD. Given the observational, unadjusted design, these associations are hypothesis-generating and cannot establish causality.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Perioperative switching to lemborexant for prevention of delirium in older cancer patients with insomnia taking GABAA receptor agonists: a retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月10日

查看全文
  • Tatsuto Terada,
  • Takatoshi Hirayama,
  • Ryoichi Sadahiro,
  • Saho Wada,
  • Junji Yamaguchi,
  • Eri Nishikawa,
  • Rika Nakahara,
  • Shinsuke Washizuka,
  • Hiromichi Matsuoka

摘要

Purpose

Postoperative delirium (POD) occurs in about one-third of patients and the incidence increases with age. The rate of missed delirium is 60%–70%, and there has recently been a shift from early detection and treatment to preventive strategies to reduce risk. While GABAA receptor agonists (GRAs) are a risk factor for delirium, discontinuation may also worsen delirium through withdrawal or worsening of insomnia. This study aimed to evaluate the effect of switching from daily preoperative GRA therapy to lemborexant monotherapy on the incidence of postoperative delirium.

Methods

A retrospective study was conducted in cancer patients aged ≥ 75 years who visited the Department of Psycho-Oncology at the National Cancer Center Hospital in Japan and were taking a GRA daily for insomnia before surgery under general anesthesia. Delirium was screened at least once daily with the Nursing Delirium Screening Scale on postoperative days 0–6 (positive if ≥ 2). We used a two-group intention-to-treat (ITT) framework, classifying patients according to a psycho-oncologist–verified preoperative switch to lemborexant.

Results

Fifty patients satisfied eligibility. POD occurred in 1/17 (5.9%) in the Switch group and 15/33 (45.5%) in the Continue group; RD −39.6 percentage points (95% CI −59.9 to −19.2), RR 0.13 (95% CI 0.02–0.90), OR 0.08 (95% CI 0.01–0.63), p = 0.005.

Conclusion

A preoperative switch policy to lemborexant monotherapy was associated with a lower observed risk of POD. Given the observational, unadjusted design, these associations are hypothesis-generating and cannot establish causality.